Tag: Vasospasm

According to the American Heart Association and American Stroke Association guidelines, a calcium channel blocker is the only pharmacological treatment with established effectiveness for improving outcomes in patients following a subarachnoid hemorrhage. The specific drug used for this purpose is nimodipine, administered to reduce the risk of delayed cerebral ischemia (DCI) caused by vasospasm.

Coronary artery vasospasm (CAVS) is most prevalent in individuals aged 40 to 70. This article explores a primary treatment: what calcium channel blockers are used for vasospasms, detailing their mechanism, types, and applications in conditions like cerebral and coronary artery spasms.

Subarachnoid hemorrhage (SAH) is a devastating type of stroke, with approximately 55% of patients being under the age of 55 when the event occurs. The primary pharmacological intervention used to manage this condition is nimodipine, answering the critical question: what is the drug of choice for subarachnoid hemorrhage? This calcium channel blocker is a cornerstone of treatment, aiming to improve neurological outcomes and prevent complications.

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating condition with a 1-month mortality rate of 10–40%. Effective pharmacological interventions are crucial, in addition to surgical or endovascular repair, to effectively treat aneurysmal subarachnoid hemorrhage and its cascade of secondary complications. These treatment strategies focus on stabilizing the patient, securing the ruptured aneurysm, and preventing or managing complications like delayed cerebral ischemia and hydrocephalus.

According to the American Heart Association/American Stroke Association (AHA/ASA), nimodipine is a key medication to improve neurological outcomes following aneurysmal subarachnoid hemorrhage. When considering **what medication is given after aneurysm** treatment, the approach is highly dependent on whether the aneurysm was ruptured and its location. This article provides a general overview of the different medications and their purposes in post-aneurysm care.

About 30,000 people in the United States suffer a brain aneurysm rupture each year, which is one every 18 minutes. When this critical event occurs, understanding **what is the drug of choice for a brain aneurysm** becomes essential for managing life-threatening complications.

Affecting 3% to 5% of adults worldwide, Raynaud's phenomenon is a common vasospastic condition [1.7.4]. A key question for many is: **Can lisinopril cause Raynaud's disease?** While uncommon, this ACE inhibitor has been linked to causing or exacerbating symptoms in some individuals [1.2.1, 1.2.2].

According to clinical data from trials, approximately 15% of patients taking capecitabine reported experiencing headaches. Yes, capecitabine can cause headaches, and while they are often mild, they can sometimes be more severe, requiring specific management strategies. This article explores why this happens, how to differentiate it from other causes, and what can be done to find relief.

First isolated in 1848 from the opium poppy, the drug papaverine, formerly sold under the brand name Pavabid, is a vasodilator used to treat conditions caused by poor blood flow and muscle spasms. This article explores what is pavabid used for, its mechanism, and current status in medicine.

First isolated from the opium poppy in 1848, papaverine is a smooth muscle relaxant that is chemically and pharmacologically distinct from the narcotic opium alkaloids. It is primarily used to treat various conditions involving spasms of the smooth muscles in blood vessels and internal organs.